The startup is developing a new class of flexible therapeutics and diagnostics that can bind multiple targets simultaneously, specifically for oncology, metabolic diseases, and neurodegenerative disorders. This technology enables early disease diagnosis and targeted treatment, improving patient outcomes through enhanced therapeutic precision.
Funding
$66.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PFounders
Product
Problem
Current therapeutic antibody approaches often face challenges related to resistance, inadequate efficacy, and off-target side effects in treating autoimmune diseases, cancer, inflammatory conditions, and infectious diseases. Traditional antibody designs may lack the necessary multivalency and multispecificity to effectively engage multiple disease targets simultaneously.
Solution
Hinge Bio is developing a new class of therapeutics based on its GEM-DIMER™ platform, designed to overcome the limitations of conventional antibody therapies. The GEM-DIMER™ technology enables cooperative binding to disease targets, resulting in enhanced activity. This platform allows for creating molecules with increased multivalency and multispecificity compared to traditional methods, leading to improved safety and efficacy profiles. Hinge Bio's approach aims to create therapeutics with novel functionalities, addressing the unmet needs in treating complex diseases.
Target Audience
Hinge Bio's therapeutics target patients and healthcare providers seeking more effective and safer treatment options for autoimmune diseases, cancer, inflammatory conditions, and infectious diseases.
Features
- GEM-DIMER™ platform enabling cooperative binding for enhanced therapeutic activity
- Increased multivalency and multispecificity compared to conventional antibodies
- Topologically engineered, superdimeric antibody NK engagers and T cell engagers for B cell depletion
- Potential applications in autoimmunity, cancer, inflammatory diseases, and infectious diseases
- Intellectual property portfolio covering novel compositions of matter and methods for synthesis and use